171 related articles for article (PubMed ID: 32632699)
21. Predictive value of Borrelia burgdorferi IgG antibody levels in patients referred to a tertiary Lyme centre.
Zwerink M; Zomer TP; van Kooten B; Blaauw G; van Bemmel T; van Hees BC; Vermeeren YM; Landman GW
Ticks Tick Borne Dis; 2018 Mar; 9(3):594-597. PubMed ID: 29422448
[TBL] [Abstract][Full Text] [Related]
22. Laboratory diagnosis of Lyme borreliosis in Scottish patients: a novel approach.
Mavin S; Watson EJ; Evans R
Br J Biomed Sci; 2014; 71(2):51-4. PubMed ID: 24974678
[TBL] [Abstract][Full Text] [Related]
23. Prospective study of serologic tests for lyme disease.
Steere AC; McHugh G; Damle N; Sikand VK
Clin Infect Dis; 2008 Jul; 47(2):188-95. PubMed ID: 18532885
[TBL] [Abstract][Full Text] [Related]
24. The VlsE (IR6) peptide ELISA in the serodiagnosis of lyme facial paralysis.
Peltomaa M; McHugh G; Steere AC
Otol Neurotol; 2004 Sep; 25(5):838-41. PubMed ID: 15354020
[TBL] [Abstract][Full Text] [Related]
25. The Performance of Nine Commercial Serological Screening Assays for the Diagnosis of Lyme Borreliosis: a Multicenter Modified Two-Gate Design Study.
Hoeve-Bakker BJA; Jonker M; Brandenburg AH; den Reijer PM; Stelma FF; van Dam AP; van Gorkom T; Kerkhof K; Thijsen SFT; Kremer K
Microbiol Spectr; 2022 Apr; 10(2):e0051022. PubMed ID: 35297658
[TBL] [Abstract][Full Text] [Related]
26. Effect of Borrelia burgdorferi genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease.
Wormser GP; Liveris D; Hanincová K; Brisson D; Ludin S; Stracuzzi VJ; Embers ME; Philipp MT; Levin A; Aguero-Rosenfeld M; Schwartz I
Clin Infect Dis; 2008 Oct; 47(7):910-4. PubMed ID: 18724824
[TBL] [Abstract][Full Text] [Related]
27. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay.
Branda JA; Linskey K; Kim YA; Steere AC; Ferraro MJ
Clin Infect Dis; 2011 Sep; 53(6):541-7. PubMed ID: 21865190
[TBL] [Abstract][Full Text] [Related]
28. Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis.
Marangoni A; Moroni A; Accardo S; Cevenini R
Eur J Clin Microbiol Infect Dis; 2008 May; 27(5):349-54. PubMed ID: 18197445
[TBL] [Abstract][Full Text] [Related]
29. Improved Serodiagnostic Performance for Lyme Disease by Use of Two Recombinant Proteins in Enzyme-Linked Immunosorbent Assay Compared to Standardized Two-Tier Testing.
Bradshaw GL; Thueson RK; Uriona TJ
J Clin Microbiol; 2017 Oct; 55(10):3046-3056. PubMed ID: 28768731
[TBL] [Abstract][Full Text] [Related]
30. Optimizing use of multi-antibody assays for Lyme disease diagnosis: A bioinformatic approach.
Porwancher R; Landsberg L
PLoS One; 2021; 16(9):e0253514. PubMed ID: 34499659
[TBL] [Abstract][Full Text] [Related]
31. Persistent Anti-
Markowicz M; Reiter M; Gamper J; Stanek G; Stockinger H
Microbiol Spectr; 2021 Dec; 9(3):e0102021. PubMed ID: 34937165
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of lyme borreliosis.
Aguero-Rosenfeld ME; Wang G; Schwartz I; Wormser GP
Clin Microbiol Rev; 2005 Jul; 18(3):484-509. PubMed ID: 16020686
[TBL] [Abstract][Full Text] [Related]
33. C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden.
Tjernberg I; Krüger G; Eliasson I
Eur J Clin Microbiol Infect Dis; 2007 Jan; 26(1):37-42. PubMed ID: 17180348
[TBL] [Abstract][Full Text] [Related]
34. Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context.
Can Commun Dis Rep; 2020 May; 46(5):125-131. PubMed ID: 32558809
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of in vivo expressed Borrelia burgdorferi antigens for improved IgM serodiagnosis of early Lyme disease.
Brandt KS; Ullmann AJ; Molins CR; Horiuchi K; Biggerstaff BJ; Gilmore RD
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):196-202. PubMed ID: 30344068
[TBL] [Abstract][Full Text] [Related]
36. Modified interpretation criteria significantly improve performance of commercially available confirmatory assays for the serodiagnosis of Lyme borreliosis: a case-control study with clinically defined serum samples.
Hauser U
Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):529-539. PubMed ID: 30715667
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Performance of the Novel BioPlex Lyme Serological Assays in European Patients with Lyme Disease.
Baarsma ME; Ursinus J; Zaaijer HL; Kuiper H; Hovius JW
J Clin Microbiol; 2021 Jun; 59(7):e0320520. PubMed ID: 33883179
[TBL] [Abstract][Full Text] [Related]
38. C6 Peptide-Based Multiplex Phosphorescence Analysis (PHOSPHAN) for Serologic Confirmation of Lyme Borreliosis.
Pomelova VG; Korenberg EI; Kuznetsova TI; Bychenkova TA; Bekman NI; Osin NS
PLoS One; 2015; 10(7):e0130048. PubMed ID: 26147441
[TBL] [Abstract][Full Text] [Related]
39. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.
Wormser GP; Schriefer M; Aguero-Rosenfeld ME; Levin A; Steere AC; Nadelman RB; Nowakowski J; Marques A; Johnson BJ; Dumler JS
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):9-15. PubMed ID: 23062467
[TBL] [Abstract][Full Text] [Related]
40. Recombinant OspC from Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii in the serodiagnosis of Lyme borreliosis.
Panelius J; Lahdenne P; Heikkilä T; Peltomaa M; Oksi J; Seppälä I
J Med Microbiol; 2002 Sep; 51(9):731-739. PubMed ID: 12358063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
